Candel therapeutics reports both prolonged median overall survival and long tail of survival in phase 2a clinical trial of can-2409 in advanced non-small cell lung cancer (nsclc) patients non-responsive to immune checkpoint inhibitor (ici) treatment

Needham, mass., march 26, 2025 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced final survival data from a phase 2a clinical trial of can-2409 in patients with stage iii/iv nsclc, inadequately responding to ici treatment. mos was 24.5 months in 46 evaluable patients receiving 2 courses of can-2409 (per protocol population; cohort 1 and 2) and 21.5 months in evaluable patients from cohort 2 (n=41) that presented with progressive disease at baseline, despite ici treatment. mos in patients with progressive disease despite ici treatment, was 9.8-11.8 months in other studies, including those with standard of care of docetaxel chemotherapy, which has a very poor prognosis, did not exceed 12 months in other published studies.(1, 2 ) this final analysis included extended follow-up data (1 year after the previous data cut) with a median follow up time for the per protocol population of 32.4 months. data showed a sizable percentage of patients with survival exceeding 24 months, evidence of a long tail of survival, with 37% of patients with progressive disease despite treatment with ici alive 2 years after can-2409 administration.
CADL Ratings Summary
CADL Quant Ranking